CONTRIBUTION OF ADRENERGIC-MECHANISMS TO GLUCOSE COUNTERREGULATION IN HUMANS

被引:44
作者
DEFEO, P
PERRIELLO, G
TORLONE, E
FANELLI, C
VENTURA, MM
SANTEUSANIO, F
BRUNETTI, P
GERICH, JE
BOLLI, GB
机构
[1] UNIV PERUGIA, IST PATOL MED, VIA E DAL POZZO, I-06100 PERUGIA, ITALY
[2] UNIV PITTSBURGH, CLIN RES CTR, DEPT MED, PITTSBURGH, PA 15261 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY | 1991年 / 261卷 / 06期
关键词
CATECHOLAMINES; GLUCAGON; HYPOGLYCEMIA; CORTISOL; GROWTH HORMONE;
D O I
10.1152/ajpendo.1991.261.6.E725
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
To assess the role of adrenergic mechanisms during prolonged hypoglycemia, eight normal subjects were studied on six occasions. In study 1, insulin was infused subcutaneously (15 mU.m-2.min-1 for 12 h), and plasma glucose concentration (PG) decreased from 89 +/- 2 to 50 +/- 1 mg/dl. In study 2 (insulin as in study 1 + propranolol and phentolamine + variable glucose to maintain PG as in study 1), the rate of hepatic glucose production (HGO, [3-H-3]glucose) was approximately 30% lower after 1.5 h, and the rate of peripheral glucose utilization (GU) was approximately 15% greater after 5 h. To quantitate the effects of adrenergic mechanisms on glucose counterregulation, in a control study (study 3), glucoregulatory hormone secretion was blocked, and the hormones were reinfused to reproduce study 1. When alpha- and beta-blockade plus variable glucose were superimposed to study 3 (study 4), HGO was approximately 25% lower (after 2 h), and GU was approximately 10% greater (after 6 h) vs. study 3. When glucose was not infused to match PG of study 3 (study 5), severe hypoglycemia developed (PG at 7 h 36 +/- 2 vs. 62 +/- 3 mg/dl). Finally, when glucose was not infused during alpha- and beta-blockade of study 2 (study 6), PG was 49 +/- 3 mg/dl at 7 h vs. 65 +/- 3 mg/dl of the control study (study 1), despite greater secretion of glucagon, growth hormone, and cortisol. It is concluded that adrenergic mechanisms play a key counterregulatory role, even in the presence of appropriate responses of glucagon and that greater increases in glucagon (and other counterregulatory hormones) cannot compensate fully for absent contribution of adrenergic mechanisms to counterregulation.
引用
收藏
页码:E725 / E736
页数:12
相关论文
共 38 条
[1]   RARITY OF A MARKED DAWN PHENOMENON IN DIABETIC SUBJECTS TREATED BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION [J].
BENDING, JJ ;
PICKUP, JC ;
COLLINS, ACG ;
KEEN, H .
DIABETES CARE, 1985, 8 (01) :28-33
[2]  
BENDTSON I, 1988, ACTA MED SCAND, V223, P543
[3]   ADRENERGIC RECEPTOR CONTROL MECHANISM FOR GROWTH HORMONE SECRETION [J].
BLACKARD, WG ;
HEIDINGSFELDER, SA .
JOURNAL OF CLINICAL INVESTIGATION, 1968, 47 (06) :1407-+
[4]   ROLE OF HEPATIC AUTO-REGULATION IN DEFENSE AGAINST HYPOGLYCEMIA IN HUMANS [J].
BOLLI, G ;
DEFEO, P ;
PERRIELLO, G ;
DECOSMO, S ;
VENTURA, M ;
CAMPBELL, P ;
BRUNETTI, P ;
GERICH, JE .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (05) :1623-1631
[5]   IMPORTANT ROLE OF ADRENERGIC-MECHANISMS IN ACUTE GLUCOSE COUNTER-REGULATION FOLLOWING INSULIN-INDUCED HYPOGLYCEMIA IN TYPE-1 DIABETES - EVIDENCE FOR AN EFFECT MEDIATED BY BETA-ADRENORECEPTORS [J].
BOLLI, G ;
DEFEO, P ;
COMPAGNUCCI, P ;
CARTECHINI, MG ;
ANGELETTI, G ;
SANTEUSANIO, F ;
BRUNETTI, P .
DIABETES, 1982, 31 (07) :641-647
[6]   ABNORMAL GLUCOSE COUNTERREGULATION IN INSULIN-DEPENDENT DIABETES-MELLITUS - INTERACTION OF ANTI-INSULIN ANTIBODIES AND IMPAIRED GLUCAGON AND EPINEPHRINE SECRETION [J].
BOLLI, G ;
DEFEO, P ;
COMPAGNUCCI, P ;
CARTECHINI, MG ;
ANGELETTI, G ;
SANTEUSANIO, F ;
BRUNETTI, P ;
GERICH, JE .
DIABETES, 1983, 32 (02) :134-141
[7]   GLUCOSE COUNTERREGULATION DURING PROLONGED HYPOGLYCEMIA IN NORMAL HUMANS [J].
BOLLI, GB ;
GOTTESMAN, IS ;
CRYER, PE ;
GERICH, JE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1984, 247 (02) :E206-E214
[8]  
BOLLI GB, 1984, NEW ENGL J MED, V310, P1706, DOI 10.1056/NEJM198406283102605
[9]   GROWTH-HORMONE, CORTISOL, OR BOTH ARE INVOLVED IN DEFENSE AGAINST, BUT ARE NOT CRITICAL TO RECOVERY FROM, HYPOGLYCEMIA [J].
BOYLE, PJ ;
CRYER, PE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (03) :E395-E402
[10]  
CRYER PE, 1985, NEW ENGL J MED, V313, P232